首页  >  学科前沿 {{articleInfo.dynamicName}}  > 国际TOP10药学期刊文章信息 (2024年1月)

国际TOP10药学期刊文章信息 (2024年1月)

{{releTime.slice(0,10)}}     来源:药物治疗网     编辑:石达理     阅读量:17790

一、临床药理学与治疗学 (2024年第115卷第1期)

January 2024 - Volume 115 - Issue 1 (2024年1月第115卷第1期)
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2024/115/1

Editorial(社论)
1. 在临床试验中广泛实施“家中取样”:是什么阻碍了我们?
(Broadly Implementing “At-Home Sampling” in Clinical Trials: What's Holding Us Back?)
作者:Amita Joshi* (Vice President, Head of Clinical Pharmacology, Genentech Inc, USA)

Perspective(视角)
1. 通过立法“内部标签”保护仿制药的适时竞争
(Preserving Timely Generic Drug Competition with Legislation on “Skinny Labeling”)
作者:S. Sean Tu* (West Virginia University College of Law, USA)
2. 定量系统药理学模型验证没有诀窍,而是风险和成本之间的平衡行为
(No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost)
作者:Vincent Lemaire* (Clinical Pharmacology, Genentech, USA)

Reviews(综述)
1. 靶向和免疫肿瘤治疗的肿瘤联合剂量研究设计
(Oncology Combination Dose-Finding Study Design for Targeted and Immuno-Oncology Therapies)
作者:Li Zhou* (Clinical Pharmacology, Oncology Research and Development, Pfizer Inc., USA)
2. 挽救成人肿瘤研发中停用的药物,以造福儿童和青少年癌症患者—加速多方利益相关者共识
(Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus)
作者:Teresa de Rojas* (ACCELERATE, Belgium)

Research(研究)
1. 以患者为中心的微采样支持Paxlovid临床开发:桥接和实施
(Patient Centric Microsampling to Support Paxlovid Clinical Development: Bridging and Implementation)
作者:Katty Wan* (Pfizer Inc, USA)
2. 基于模型引导凋亡蛋白抑制剂Xevinapant与顺铂联合放疗治疗局部晚期头颈部鳞状细胞癌的III期推荐剂量
(Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck)
作者:Yulia Vugmeyster* (EMD Serono, USA)
3. 结合功能内窥镜和质谱的新型平台定量分析肿瘤缺氧区三氟尿苷的浓度
(Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry)
作者:Shigehiro Koganemaru, Masahiro Yasunaga* (Department of Experimental Therapeutics, National Cancer Center Hospital East, Japan; Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Japan)
4. 替格瑞洛可增加乳腺癌耐药蛋白底物瑞舒伐他汀的暴露
(Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin)
作者:Minna Lehtisalo, Mikko Niemi* (Department of Clinical Pharmacology, University of Helsinki, Finland)
5. 吸烟的HIV感染者停用依非韦伦治疗后尼古丁代谢物比率下降
(Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz-Based Therapy in People With HIV Who Smoke)
作者:Dominique Medaglio, Robert Gross* (Department of Epidemiology, Biostatistics & Informatics, University of Pennsylvania, USA)
6. 中和抗体水平与SARS-CoV-2感染保护的相关性:一项建模分析
(Neutralizing Antibody Levels as a Correlate of Protection Against SARS-CoV-2 Infection: A Modeling Analysis)
作者:Guillaume Lingas, Jérémie Guedj* (Université Paris Cité, IAME, INSERM, France)
7. 2型糖尿病患者使用SGLT-2抑制剂后糖尿病视网膜病变的风险:一项全国性人群队列研究
(Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study)
作者:Shih-Ting Huang* (Division of Nephrology, Taichung Veterans General Hospital, China)
8. 他克莫司药代动力学与肾移植患者肠道菌群多样性相关:一项前瞻性横断面研究的结果
(Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross-Sectional Study)
作者:Alexandra L. Degraeve, Laure Elens* (Department of Integrated PharmacoMetrics, PharmacoGenomics and PharmacoKinetics, Louvain Drug Research Institute, Université Catholique de Louvain, Belgium)
9. Treosulfan暴露可预测接受异基因造血细胞移植的重型β地中海贫血患者的无地中海贫血生存率
(Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation)
作者:Aswin Anand Pai, Poonkuzhali Balasubramanian* (Department of Hematology, Christian Medical College, India)
10. 高剂量与标准剂量流感疫苗与心肺住院或死亡率的比较:使用保险索赔数据模拟INVESTED试验
(High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data)
作者:Mehdi NajafZadeh, HoJin Shin* (Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, USA)
11. 阿瑞匹坦对睾丸癌症患者依托泊苷的药代动力学影响:一项确定无临床相关相互作用的药代动力学研究
(Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction)
作者:Jeffrey Strik, Nielka P. van Erp* (Department of Pharmacy, Radboud University Medical Center Research Institute for Medical Innovation, Radboud University Medical Center, The Netherlands)
12. 基因治疗试验参与者长期随访实践和统计考虑
(Practical and Statistical Considerations for the Long Term Follow-Up of Gene Therapy Trial Participants)
作者:Maximilian Rohde, Avery McIntosh* (Pfizer Inc., USA)
13. 使用氟喹诺酮类药物与二尖瓣或主动脉瓣反流风险之间的关系:一项全国性队列研究
(Association Between Use of Fluoroquinolones and Risk of Mitral or Aortic Valve Regurgitation: A Nationwide Cohort Study)
作者:Yaa-Hui Dong* (Department of Pharmacy, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, China)

二、药理学评论

January 2024 - Volume 76 - Issue 1 (2024年1月第76卷第1期)
https://pharmrev.aspetjournals.org/content/76/1

Review Articles(综述文章)
1. 帕金森病中微生物群对疼痛感知的调节
(Regulation of Pain Perception by Microbiota in Parkinson Disease)
作者:Zulmary Manjarres (Laboratorio de Neuroinmunología, Centro Científico y Tecnológico de Excelencia Ciencia & Vida, Fundación Ciencia & Vida, Chile)
2. 非激素类男性避孕药的发展—进展策略
(Nonhormonal Male Contraceptive Development—Strategies for Progress)
作者:Logan Nickels (Male Contraceptive Initiative, USA)
3. 肝源性全身性疾病核酸疗法的肝脏靶向作用
(Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin)
作者:Anagha Gogate (Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, USA)
4. 对抗耐药病原体的卤化抗菌剂
(Halogenated Antimicrobial Agents to Combat Drug-Resistant Pathogens)
作者:Olajide Sunday Faleye (School of Chemical Engineering and Department of Medical Biotechnology, Yeungnam University, Korea)
5. SLC6A15-SLC6A20中性氨基酸转运蛋白亚家族:功能、疾病及其治疗相关性
(The SLC6A15–SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance)
作者:Jędrzej Kukułowicz (Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Poland)

三、先进药物输送评论 (2024年第204卷)

January 2024 - Volume 204 (2024年1月第204卷)
https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/204/suppl/C

Review article(综述文章)
1. 纳米颗粒药物递送的原位细胞搭便车
(In situ cellular hitchhiking of nanoparticles for drug delivery)
作者:Edidiong Udofa, Zongmin Zhao* (Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, USA)
2. 用于纳米药物合理设计的先进光学成像技术
(Advanced optical imaging for the rational design of nanomedicines)
作者:Ana Ortiz-Perez, Lorenzo Albertazzi* (Department of Biomedical Engineering, Institute of Complex Molecular Systems, Eindhoven University of Technology, the Netherlands)
3. 二维纳米材料与细胞屏障的相互作用:膜附着和细胞内运输
(Interaction of 2D nanomaterial with cellular barrier: Membrane attachment and intracellular trafficking)
作者:Li Miao, Shane Browne* (Department of Mechanical, Manufacturing and Biomedical Engineering, Trinity College Dublin, Ireland; CÚRAM, Centre for Research in Medical Devices, National University of Ireland, Ireland)
4. 改造代谢以调节免疫力
(Engineering metabolism to modulate immunity)
作者:Senta M. Kapnick, Christopher M. Jewell* (Fischell Department of Bioengineering, University of Maryland, USA)
5. 微泡辅助超声在内耳给药中的应用
(Microbubble-assisted ultrasound for inner ear drug delivery)
作者:Fabrice Micaletti* (ENT and Cervico-Facial Surgery Department, University Hospital Center of Tours, France)
6. 靶向肺纤维化治疗的新递送方法
(Emerging delivery approaches for targeted pulmonary fibrosis treatment)
作者:Rimpy Diwan, Md Nurunnabi* (Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas El Paso, USA)
7. 长效吸入药物:现在和未来
(Long-acting inhaled medicines: Present and future)
作者:Chengqian Zhang, Mingshi Yang* (Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark)
8. 离子液体克服物理和生物障碍的潜力
(Potentials of ionic liquids to overcome physical and biological barriers)
作者:Elfa Beaven, Yong-kyu Lee* (Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, USA; Department of Bioengineering, College of Engineering, Hanyang University, Korea)

四、药理学发展趋势 (2024年第45卷第1期)

January 2024 - Volume 45 - Issue 1 (2024年1月第45卷第1期)
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(23)X0002-9

Scientific Life(科学生活)
1. 科学家联网快速指南
(A quick guide to networking for scientists)
作者:Heather K. Beasley, Antentor Hinton Jr* (Department of Molecular Physiology and Biophysics, Vanderbilt University, USA)
2. 海报展示和会议组织:现代会议
(Poster presentations and session organization: modern conferences)
作者:Thomas C. Erren* (Institute and Policlinic for Occupational Medicine, Environmental Medicine, and Prevention Research, University Hospital of Cologne, Germany)

Reviews(综述)
1. 治疗神经炎性疾病的PPAR激动剂
(PPAR agonists for the treatment of neuroinflammatory diseases)
作者:Celene Titus, Md Tozammel Hoque, Reina Bendayan* (Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada)
2. 表观转录组学的兴起:最近的发展和未来的方向
(The rise of epitranscriptomics: recent developments and future directions)
作者:Jonas Cerneckis, Hong Yan, Hongjun Song* (Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, USA)
3. 基于计算和人工智能的药物代谢和转运预测方法
(Computational and artificial intelligence-based approaches for drug metabolism and transport prediction)
作者:Balint Dudas, Maria A. Miteva* (Université Paris Cité, France)
4. 肿瘤干细胞的生物标志物和靶向治疗
(Biomarkers and targeted therapy for cancer stem cells)
作者:Yusheng Liu, Hua Wang* (Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, USA)
5. 使用质谱成像的空间药理学
(Spatial pharmacology using mass spectrometry imaging)
作者:Presha Rajbhandari, Brent R. Stockwell* (Department of Biological Sciences, Columbia University, USA)
6. 溶酶体自噬-NLRP3炎症体交叉途径的药理学靶点
(Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads)
作者:Srinivasa Reddy Bonam, Sylviane Muller* (Department of Microbiology and Immunology, University of Texas Medical Branch, USA; CNRS-University of Strasbourg, Biotechnology and Cell Signaling, France)

五、药理学与治疗学 (2024年第253卷)

January 2024 - Volume 253 (2024年1月第253卷)
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/253/suppl/C

Review article(综述文章)
1. 干细胞在慢性肝病肝脏再生中的治疗潜力:目前视角和未来挑战
(Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges)
作者:Poonam Yadav, Amit Khurana* (Department of Pharmacology, Central University of Punjab, India)
2. 回顾我们的脚步:一项儿童自闭症的研究综述,包括其局限性和即将到来的药物干预
(Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions)
作者:Salam Salloum-Asfar* (Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar)
3. pexidartinib用于小胶质细胞衰竭和再生的再利用
(Repurposing of pexidartinib for microglia depletion and renewal)
作者:Marc-Philipp Weyer, Irmgard Tegeder* (Institute of Clinical Pharmacology, Goethe-University Frankfurt, Faculty of Medicine, Germany)
4. RNA ac4C修饰和NAT10在哺乳动物发育和人类疾病中的新作用
(Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases)
作者:Yigan Zhang, Lv Wei* (Institute of Biomedical Research, Department of Infectious Diseases, Regulatory Mechanism and Targeted Therapy for Liver Cancer Shiyan Key Laboratory, Hubei rovincial Clinical Research Center for Precise Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, China; Institute of Biophysics, Chinese Academy of Sciences, Key Laboratory of Nucleic Acid Biology, Chinese Academy of Sciences, China)
5. 高血压与痴呆:降压药在减轻疾病负担中的病理生理学和潜在效用
(Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden)
作者:Mara Lyon, Josie L. Fullerton, Lorraine M. Work* (School of Cardiovascular & Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK)
6. 精神和物质使用障碍中的有机阳离子转运体
(Organic cation transporters in psychiatric and substance use disorders)
作者:Lauren E. Honan, Lynette C. Daws* (The University of Texas Health Science Center at San Antonio, Department of Cellular & Integrative Physiology, USA)
7. TNC递送载体及其结合物的临床研究进展
(Clinical advances in TNC delivery vectors and their conjugate agents)
作者:Wujun Chen, Xiaohui Xing* (Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, China;Department of Neurosurgery, Liaocheng People's Hospital, China)
8. 靶向结缔组织生长因子在纤维化肺疾病中的治疗策略
(Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases)
作者:Takuma Isshiki, Kjetil Ask* (Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Canada)
9. TAAR1作为治疗精神疾病的新靶点
(TAAR1 as an emerging target for the treatment of psychiatric disorders)
作者:Jianfeng Liu* (School of Medicine, Wuhan University of Science and Technology, China)

六、药物 (2024年第84卷第1期)

January 2024 - Volume 84 - Issue 1 (2024年1月第84卷第1期)
https://link.springer.com/journal/40265/volumes-and-issues/84-1

Leading Article(主编文章)
1. 原发胆汁性胆管炎的新疗法
(New Therapies on the Horizon for Primary Biliary Cholangitis)
作者:Atsushi Tanaka* (Department of Medicine, Teikyo University School of Medicine, Japan)

Review Article(综述文章)
1. 巨球蛋白血症:靶向药物占据中心地位
(Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage)
作者:Shayna Sarosiek* (Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, USA)
2. 用小分子抑制剂靶向KRAS突变的胃肠道恶性肿瘤:新一代突破性疗法
(Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies)
作者:Bennett A. Caughey* (Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, USA)
3. 佩索利单抗治疗广泛性脓疱性银屑病
(Spesolimab for the Treatment of Generalized Pustular Psoriasis)
作者:Diana Bernardo, Tiago Torres* (Department of Dermatology, Centro Hospitalar Universitário do Porto, Portugal)

Systematic Review(系统综述)
1. 颞下颌关节紊乱的药理治疗:一项包括网络Meta分析在内的系统综述
(Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis)
作者:Nikolaos Christidis* (Division of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Sweden)

Original Research Article(原创研究文章)
1. Travoprost眼内植入物在降低开角型青光眼或高眼压患者局部眼压、降低药物负担方面的有效性和安全性
(Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension)
作者:John P. Berdahl, Tomas Navratil* (Vance Thompson Vision, USA; Glaukos Corporation, One Glaukos Way, USA)

AdisInsight Report(AdisInsight报告)
1. Zilucoplan:首次获批
(Zilucoplan: First Approval)
作者:Matt Shirley* (Springer Nature, New Zealand)
2. 纳鲁索拜单抗:首次获批
(Narlumosbart: First Approval)
作者:Sohita Dhillon* (Springer Nature, New Zealand)
3. Vamorolone:首次批准
(Vamorolone: First Approval)
作者:Susan J. Keam* (Springer Nature, New Zealand)

七、药理学研究 (2024年第199卷)

January 2024 - Volume 199 (2024年1月第199卷)
https://www.sciencedirect.com/journal/pharmacological-research/vol/199/suppl/C

Editorial(社论)
1. 2023年欧洲高血压协会的高血压治疗指南-诊断和治疗方法的新内容
(The 2023 European Society of Hypertension guidelines for high blood pressure – What’s new on diagnostic and therapeutic approaches)
作者:Guido Grassi* (Clinica Medica, Università Milano-Bicocca, Italy)

Review Articles(综述文章)
1. 强化处方:线粒体作为“活体药物”-定义,临床应用和行业进展
(Powering prescription: Mitochondria as “Living Drugs” – Definition, clinical applications, and industry advancements)
作者:Andrés Caicedo* (Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, Escuela de Medicina, Ecuador)
2. 中成药指南报告清单:CPM的权力
(The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM)
作者:Xuanlin Li, Yaolong Chen* (School of Basic Medical Science, Zhejiang Chinese Medical University, China; Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, China)
3. 胆道疾病引起的心脏并发症:胆道综合征的临床表现、发病机制及治疗策略综述
(Cardiac complications caused by biliary diseases: A review of clinical manifestations, pathogenesis and treatment strategies of cholecardia syndrome)
作者:Yanan Li, Guixin Zhang*, Jialin Qu* (Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, China)
4. 黄芩苷和黄芩黄素通过调节肿瘤微环境治疗癌症:综述与展望
(Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives)
作者:Ruolei Wang, Chunyan Wang, Fuwen Yuan*, Feng He* (The Center for Cancer Research, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, China)
5. 巨噬细胞相关的治疗策略:表型转换的调控和药物传递系统的构建
(Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems)
作者:Xi Wang, Yixuan Li, Jian Yang* (State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, China)
6. SIRT1/SREBP介导的脂质代谢调节
(SIRT1/SREBPs-mediated regulation of lipid metabolism)
作者:Shan Shen, Yong Wang* (Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, China)
7. 替西帕肽和司美格鲁肽治疗2型糖尿病的疗效和安全性评价与比较:贝叶斯网络Meta分析
(Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis)
作者:Yanan Ding, Guo Ma* (School of Pharmacy, Fudan University, China)
8. SIRT1是自噬调节因子:对心肌缺血-再灌注的进展和治疗的意义
(SIRT1 is a regulator of autophagy: Implications for the progression and treatment of myocardial ischemia-reperfusion)
作者:Xiaoqing Ding1, Chenyu Zhu1, Binghong Gao2* (1. School of Exercise and Health, Shanghai University of Sport, China; 2. School of Athletic Performance, Shanghai University of Sport, China)
9. 美国FDA批准的用于治疗肿瘤和非肿瘤疾病的小分子蛋白激酶抑制剂的费用
(Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases)
作者:Robert Roskoski Jr.* (Blue Ridge Institute for Medical Research, USA)
10. IUPHAR综述:阿片类药物使用障碍的数据驱动计算药物再利用方法
(IUPHAR review – Data-driven computational drug repurposing approaches for opioid use disorder)
作者:Zhenxiang Gao, Pingjian Ding, Rong Xu* (Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, USA)
11. IUPHAR-综述:经典致幻剂与当前药物使用障碍治疗模式的整合
(IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models)
作者:David B. Yaden* (Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA)
12. 从锌稳态到疾病进展:揭开神经退行性疾病之谜
(From zinc homeostasis to disease progression: Unveiling the neurodegenerative puzzle)
作者:Yong-Gang Fan*, Zhan-You Wang* (Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, China)
13. 理解和应对再现性危机—为什么我们需要研究科学家对数据的信任
(Understanding and tackling the reproducibility crisis – Why we need to study scientists’ trust in data)
作者:Michael Calnan, Martin Michaelis* (School of Social Policy, Sociology and Social Research, University of Kent, UK; School of Biosciences, University of Kent, UK)
14. 短链脂肪酸对糖尿病小鼠模型血糖和血脂水平的影响:一项系统综述和网络Meta分析
(Effects of short-chain fatty acids on blood glucose and lipid levels in mouse models of diabetes mellitus: A systematic review and network meta-analysis)
作者:Jie Zheng1, Yu An2, Yanhui Lu1* (1. School of Nursing, Peking University, China; 2. Department of Endocrinology, Beijing Chaoyang Hospital, China)

Research article(研究文章)
1. IUPHAR综述-神经性疼痛的临床前模型:评估天然大麻素受体配体的多功能特性
(IUPHAR review- Preclinical models of neuropathic pain: Evaluating multifunctional properties of natural cannabinoid receptors ligands)
作者:Khalid Benamar* (Institute of Neuroscience and Department of Neuro-behavioral Health, University of Texas Rio Grande Valley, School of Medicine, USA)
2. IUPHAR综述:Mu阿片受体调节剂治疗阿片类药物使用障碍的最新进展
(IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders)
作者:Piyusha P. Pagare, Yan Zhang* (Department of Medicinal Chemistry, Virginia Commonwealth University, USA)
3. 口服褪黑素治疗对夜班工人胰岛素抵抗和昼夜血压变异性的影响。一项双盲、随机、安慰剂对照研究
(Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study)
作者:Juliane Hannemann, Rainer Böger* (Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany)
4. 全蛋白质组筛选将钙结合蛋白S100A8/S100A9鉴定为主动脉夹层的临床相关治疗靶点
(A proteome-wide screen identifies the calcium binding proteins, S100A8/S100A9, as clinically relevant therapeutic targets in aortic dissection)
作者:Hui Jiang, Jianjun Ge* (Department of Cardiothoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, China)
5. 黄芩苷通过调节肠道菌群代谢物短链脂肪酸来规避抗PD-1耐药性
(Baicalin circumvents anti-PD-1 resistance by regulating the gut microbiota metabolite short-chain fatty acids)
作者:Zhang Yu1, Liu Xiaojia1, Cao Bangwei2*, Yan Dan2* (1. Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, China; 2. Department of Oncology, Beijing Friendship Hospital, Capital Medical University, China)
6. 天然产物多糖对癌症的抑制作用及其新机制探讨
(Harnessing natural product polysaccharides against lung cancer and revisit its novel mechanism)
作者:Wangqi Tian, Yuwei Wang* (College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave., China)
7. 既往药物过敏与特异性药物性肝损伤患者预后较差相关:一种用于风险分层的机器学习方法
(Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: A machine learning approach for risk stratification)
作者:Hao Niu, M. Isabel Lucena* (Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Spain)
8. Disease2Vec:通过疾病嵌入树编码阿尔茨海默病进展
(Disease2Vec: Encoding Alzheimer’s progression via disease embedding tree)
作者:Lu Zhang, Dajiang Zhu* (Department of Computer Science and Engineering, The University of Texas at Arlington, USA)
9. 一种修饰性核苷O6-methyl-dGTP以不依赖caspase蛋白酶的方式表现出抗胶质母细胞瘤的活性
(A modified nucleoside O6-methyl-2′-deoxyguanosine-5′-triphosphate exhibits anti-glioblastoma activity in a caspase-independent manner)
作者:Zi-Hui Wang, Jin Li, Jian-Ping Cai* (The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, China)
10. 内侧前额叶皮层锥体神经元中的多巴胺D2受体调节社交行为
(Dopamine D2 receptors in pyramidal neurons in the medial prefrontal cortex regulate social behavior)
作者:Hao Chen, Tian-Ming Gao*, Yi-Hua Chen* (Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, China)
11. 达格列净加口服司美格鲁肽治疗2型糖尿病的药理学缓解作用
(Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide)
作者:Maria Elena Lunati, Paolo Fiorina* (Division of Endocrinology, ASST Fatebenefratelli-Sacco, Italy)
12. 个体化治疗挑战时代的临床研究和药物监管:临床药理学的关键作用
(Clinical research and drug regulation in the challenging times of individualized therapies: A pivotal role of clinical pharmacology)
作者:Antonio Gómez-Outes, Aránzazu Sancho-López* (Division of Pharmacology and Clinical Drug Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Healthcare Products (AEMPS), Spain; Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda, Spain)
13. 去偶联FcRn和肿瘤对癌症恶病质免疫检查点抑制剂清除率升高的作用
(Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia)
作者:Trang T. Vu, Kyeongmin Kim, Christopher C. Coss*, Mitch A. Phelps* (Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, USA)
14. β-抑制蛋白偏向性信号传导与5-HT7受体刺激的降压作用无关:血清素的使用
(β-arrestin biased signaling is not involved in the hypotensive actions of 5-HT7 receptor stimulation: use of Serodolin)
作者:Stephanie W. Watts* (Department of Pharmacology and Toxicology, Michigan State University, USA)
15. 青少年时期频繁的低强度接触四氢大麻酚会导致小鼠对病毒感染的反应出现持续的性二态改变
(Frequent low-impact exposure to THC during adolescence causes persistent sexually dimorphic alterations in the response to viral infection in mice)
作者:Hye-Lim Lee, Daniele Piomelli* (Department of Anatomy and Neurobiology, University of California, USA)
16. 溶瘤系统在胰腺肿瘤细胞中选择性地产生氧气,以缓解缺氧并提高免疫激活
(An oncolytic system produces oxygen selectively in pancreatic tumor cells to alleviate hypoxia and improve immune activation)
作者:Yu Chen, Lei Wang* (Department of Gastroenterology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, China)

Letters to the Editor(读者来信)
1. 钠-葡萄糖共转运蛋白-2抑制剂:治疗拉福拉病的新方法?
(Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?)
作者:Paola Imbrici*, Antonella Liantonio* (Department of Pharmacy - Drug Sciences, University of Bari "Aldo Moro", Italy)
2. 基于新抗原的治疗性癌症疫苗:迈向光明的未来
(Neoantigen-based therapeutic cancer vaccine: Towards a bright future)
作者:Yuning Wang, Guo Zhao, Peiwen Ma, Shuhang Wang*, Ning Li* (Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)
3. 关于“骨痛贴片与非甾体抗炎药治疗膝关节骨性关节炎的疗效和安全性:中国一项真实世界多中心、前瞻性队列研究”的评论
(Comment on "Efficacy and safety of Gutong Patch compared with NSAIDs for knee osteoarthritis: A real-world multicenter, prospective cohort study in China")
作者:Chi-Tung Lu, Chin-Yuan Yii* (College of Medicine, China Medical University, China; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Landseed International Hospital, China)
4. 致丙戊酸的颂歌:给编辑的一封信
(An ode to valproic acid: A letter to the editor)
作者:Anna P. Shapiro-Krew* (Cleveland Clinic, Department of Psychiatry and Psychology, USA)
5. 对Wang Hung-Hsuan等人关于“骨痛贴片与非甾体抗炎药治疗膝关节骨性关节炎的疗效和安全性:中国一项真实世界的多中心前瞻性队列研究”的回复
(Response letter to Hung-Hsuan Wang et al. on efficacy and safety of Gutong patch compared with NSAIDs for knee osteoarthritis: A real-world multicenter, prospective cohort study in China)
作者:Yingjie Wang, Xisheng Weng* (Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, China)
6. 通讯:骨痛贴片与非甾体抗炎药治疗膝关节骨性关节炎的比较研究
(Correspondence: Study Comparing Gutong Patch and NSAIDs in Treating Knee Osteoarthritis)
作者:Hung-Hsuan Wang, Su-Boon Yong* (China Medical University Children's Hospital, China; Center for Allergy, Immunology, and Microbiome (A.I.M.), China Medical University Hospital, China)

Opinion(意见)
1. 溶酶体介导的耐药性—是事实还是幻觉?
(Lysosomal-mediated drug resistance – Fact or illusion?)
作者:Petr Mlejnek* (Department of Anatomy, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic)

八、抗病毒研究 (2024年第221卷)

January 2024 - Volume 221 (2024年1月第221卷)
https://www.sciencedirect.com/journal/antiviral-research/vol/221/suppl/C

Research article(研究文章)
1. 甘草查尔酮A调节病毒IRES活性抑制肠道病毒复制
(Licochalcone A regulates viral IRES activity to inhibit enterovirus replication)
作者:Yu-Ting Chuang, Jing-Yi Lin* (Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, China)
2. 两种结构相似的CYP3A抑制剂对致病性人类冠状病毒的广谱抗病毒活性
(Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro)
作者:Lara Gallucci, Andrew D. Davidson*, Iart Luca Shytaj* (School of Cellular and Molecular Medicine, University of Bristol, UK)
3. 一种新型二氮杂萘酮衍生物作为衣壳组装调节剂抑制乙型肝炎病毒的表达
(A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression)
作者:Li Yang, Youhong Hu* (Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China; University of Chinese Academy of Sciences, China)
4. 有症状的COVID-19门诊患者抗病毒治疗的疗效和安全性:系统评价和网络meta分析
(Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis)
作者:Meital Zur,  Ilan Matok* (Israeli Defense Forces Medical Corps, Israel; Pharmacoepidemiology Research Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel)
5. 卟啉和卟啉样化合物对蜱传脑炎病毒的抗病毒活性:通过光敏介导的病毒包膜破坏阻断病毒进入/融合机制
(Antiviral activity of porphyrins and porphyrin-like compounds against tick-borne encephalitis virus: Blockage of the viral entry/fusion machinery by photosensitization-mediated destruction of the viral envelope)
作者:Jiří Holoubek, Luděk Eyer* (Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Czech Republic)
6. 核受体RORγ亚型1作为基于胆固醇水平调节的新型宿主定向抗病毒靶点的验证
(Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels)
作者:Christina Wangen, Friedrich Hahn* (Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany)
7. 干扰素受体-1异构体对干细胞源性肝细胞中基因表达和HBV复制的影响存在差异
(Interferon lambda receptor-1 isoforms differentially influence gene expression and HBV replication in stem cell-derived hepatocytes)
作者:Laura A. Novotny, Eric G. Meissner* (Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, USA)
8. 在细胞培养和仓鼠中,纳米体对多种刺突变体和吸入含纳米体的气溶胶可中和SARS-CoV-2
(Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters)
作者:Metin Aksu, Dirk Görlich* (Max Planck Institute for Multidisciplinary Sciences, Dept. of Cellular Logistics, Germany)
9. 在新生小鼠模型中研究柯萨奇病毒B6株的毒力和抗病毒治疗
(Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model)
作者:Changjian Fang, Wei Wang* (State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, China)
10. 对非洲猪瘟病毒组蛋白样蛋白(pA104R) β链DNA结合区进行靶向诱变,可降低其DNA结合活性和抗体识别能力
(Targeted mutagenesis of the β-strand DNA binding region of African swine fever virus histone-like protein (pA104R) impairs DNA-binding activity and antibody recognition)
作者:Ana Catarina Urbano, Fernando Ferreira* (CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Portugal)
11. 普拉曲沙抑制水痘带状疱疹病毒和水疱性口炎病毒的复制:老狗的新把戏
(Pralatrexate inhibited the replication of varicella zoster virus and vesicular stomatitis virus: An old dog with new tricks)
作者:Jing Wu, Deyan Chen* (Medical School of Nanjing University, China)
12. 去泛素酶USP39通过去泛素化和稳定包膜蛋白促进SARS-CoV-2复制
(Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein)
作者:Xiang Chen, Zhaolong Li* (Institute of Virology and AIDS Research, The First Hospital of Jilin University, China; Department of Infectious Diseases, Infectious Diseases and Pathogen Biology Center, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, The First Hospital of Jilin University, China)
13. 染色质结合蛋白HMGN1通过调节组蛋白3的磷酸化促进HBV cccDNA的转录和复制
(Chromatin binding protein HMGN1 promotes HBV cccDNA transcription and replication by regulating the phosphorylation of histone 3)
作者:Tan Ming, Chen Juan* (Chongqing Key Laboratory of Child Infection and Immunity, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Department of Infectious Diseases, The Children's Hospital of Chongqing Medical University, Chongqing Medical University, China; The Key Laboratory of Molecular Biology of Infectious Diseases Designated by the Chinese Ministry of Education, Chongqing Medical University, China)
14. 缺乏CD163 PSTII结构域编码外显子13的转基因猪对PRRSV感染具有完全抗性
(Genetically modified pigs lacking CD163 PSTII-domain-coding exon 13 are completely resistant to PRRSV infection)
作者:Brianna Salgado, Alberto Brandariz-Nuñez* (Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, USA)
15. 干扰素-α治疗慢性乙型肝炎的机制及提高疗效的潜在途径
(Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy)
作者:Qiong Zhao, Ju-Tao Guo* (Baruch S. Blumberg Institute, USA)
16. 过氧化物酶体在病毒与哺乳动物细胞之间相互作用中的不同作用
(The diverse roles of peroxisomes in the interplay between viruses and mammalian cells)
作者:Hui Jiang, Yingjie Sun*, Chan Ding* (Department of Avian Infectious Diseases, Shanghai Veterinary Research Institute. Chinese Academy of Agricultural Science, China)
17. 以高遏制病毒为重点的大规模复合文库的高内容筛选策略
(High content screening strategies for large-scale compound libraries with a focus on high-containment viruses)
作者:Chandru Subramani, Tarani Kanta Barman* (Department of Pathology, University of Texas Medical Branch, USA)
18. ESCRT机制与病毒感染
(ESCRT machinery and virus infection)
作者:Jun Dai, Xusheng Qiu* (Experimental Animal Center, Zunyi Medical University, China; Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, China)
19. 呼吸道合胞病毒药物发现与开发的现状与挑战
(Current state and challenges in respiratory syncytial virus drug discovery and development)
作者:Gang Zou* (Shanghai Ark Biopharmaceutical Co., Ltd, China)
20. 广泛中和抗体对抗流感病毒感染
(Broadly neutralizing antibodies to combat influenza virus infection)
作者:Xiaoyu Sun* (Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Medical College, Fudan University, China)

九、英国药理学杂志 (2024年第181卷第1-2期)

(一)January 2024 - Volume 181 - Issue 1 (2024年1月第181卷第1期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/1

Review Article(综述文章)
1.靶向加速肺老化治疗慢性阻塞性肺疾病引起的神经病理合并症
(Targeting accelerated pulmonary ageing to treat chronic obstructive pulmonary disease-induced neuropathological comorbidities)
作者:Simone N. De Luca, Ross Vlahos* (Centre for Respiratory Science and Health, School of Health & Biomedical Sciences, RMIT University, Australia)

Research Article(研究文章)
1. 替格瑞洛在P2Y12受体上的反向激动剂活性与其内源性激动剂5′-二磷酸腺苷相比是不可逆的
(Ticagrelor inverse agonist activity at the P2Y12 receptor is non-reversible versus its endogenous agonist adenosine 5´-diphosphate)
作者:Jawad Khalil, Stuart J. Mundell* (School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, UK)
2. 敲除slco2b1和人源化SLCO2B1对大鼠体内粪卟啉I和III水平的影响
(Influence of Slco2b1-knockout and SLCO2B1-humanization on coproporphyrin I and III levels in rats)
作者:Jonny Kinzi, Henriette E. Meyer zu Schwabedissen* (Biopharmacy, Department of Pharmaceutical Sciences, University of Basel, Switzerland)
3. 新型金属化合物-β-内酰胺酶抑制剂恢复碳青霉烯类对新德里金属内酰胺酶-1 (NDM-1)细菌的敏感性
(Novel metallo-β-lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo-lactamase-1 (NDM-1)-harbouring bacteria)
作者:Yan Guo, Jianfeng Wang* (State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, College of Veterinary Medicine, Jilin University, China)
4. 乙酰唑胺和托吡酯通过不同机制降低颅内压:急性和慢性给药的效果
(Acetazolamide and topiramate lower intracranial pressure through differential mechanisms: The effect of acute and chronic administration)
作者:Connar Stanley James Westgate, Sajedeh Eftekhari* (Danish Headache Center, Department of Neurology, Glostrup Research Institute, Rigshospitalet-Glostrup, University of Copenhagen, Denmark)
5. 食欲素2受体拮抗剂性别依赖性改善tau转基因小鼠的睡眠/觉醒和认知表现
(Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice)
作者:Ryan J. Keenan, Daniel Hoyer* (Florey Institute of Neuroscience and Mental Health, Parkville, Australia)
6. 一种新的EGFR抑制剂HNPMI通过调控结肠癌中的BCL-2/BAX和p53来调节细胞凋亡和肿瘤发生
(A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer)
作者:Jeyalakshmi Kandhavelu, Clement Penny* (Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, South Africa)
7. AhR-STAT3-HO-1 /COX-2信号通路可能限制小鼠铁死亡,改善小鼠肝脏中hMSC的积累和疗效
(AhR–STAT3–HO-1/COX-2 signalling pathway may restrict ferroptosis and improve hMSC accumulation and efficacy in mouse liver)
作者:Li Han, Guoyu Pan* (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China)
8. erenumab在两个降钙素基因相关肽反应受体上的药理学特征
(Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors)
作者:Michael L. Garelja, Debbie L. Hay* (Department of Pharmacology and Toxicology, University of Otago, New Zealand)
9. 乳杆菌通过色氨酸产生的吲哚代谢物抑制芳烃受体途径改善膜性肾病
(Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites)
作者:Hua Miao, Fei Liu* (School of Pharmacy, Zhejiang Chinese Medical University, China; Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)

Commentary(评论)
1. 系统综述最佳工具和实践指南
(Guidance to best tools and practices for systematic reviews)
作者:Kat Kolaski* (Departments of Orthopaedic Surgery, Pediatrics, and Neurology, Wake Forest School of Medicine, USA)

(二)January 2024 - Volume 181 - Issue 2 (2024年1月第181卷第2期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/2

Cancer Microenvironment And Pharmacological Interventions-Editorial (癌症微环境和药物干预-社论)
1. 癌症微环境和药物干预
(Cancer microenvironment and pharmacological interventions)
作者:Mark T. S. Williams* (Department of Biological and Biomedical Sciences, Glasgow Caledonian University, UK)

Cancer Microenvironment And Pharmacological Interventions-Themed Issue Review (癌症微环境和药物干预-主题刊综述)
1. 骨髓间质成纤维细胞和间充质干细胞支持急性髓系白血病细胞并促进治疗抵抗
(Stromal bone marrow fibroblasts and mesenchymal stem cells support acute myeloid leukaemia cells and promote therapy resistance)
作者:Katerina E. Miari, Mark T. S. Williams* (Charles Oakley Laboratories, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, UK)
2. 间充质干细胞和癌症相关成纤维细胞作为乳腺癌的治疗策略
(Mesenchymal stem cells and cancer-associated fibroblasts as a therapeutic strategy for breast cancer)
作者:Francisco Raúl Borzone, Norma Alejandra Chasseing* (Laboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina)
3. 基于程序性死亡配体-1分布和功能的肿瘤免疫治疗优化
(Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function)
作者:Wei Zou, Zhonghong Wei* (Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, China)
4. 了解白血病干细胞及其微环境之间的相互作用以改善治疗方法
(Understanding the interaction between leukaemia stem cells and their microenvironment to improve therapeutic approaches)
作者:Leandro M. Martinez, Monica L. Guzman* (Division of Hematology and Medical Oncology, Weill Cornell Medical College, USA)
5. 微环境随时间改变导致髓系恶性肿瘤
(Micro-environment alterations through time leading to myeloid malignancies)
作者:Kudzai Nyamondo, Helen Wheadon* (Paul O'Gorman Leukaemia Research Centre, Gartnavel Hospital, University of Glasgow, UK)

Cancer Microenvironment And Pharmacological Interventions-Invited Review (癌症微环境和药物干预-特约综述)
1. 靶向整合素治疗耐药急性髓性白血病
(Targeting integrins in drug-resistant acute myeloid leukaemia)
作者:Heather A. Ogana, Yong-Mi Kim* (Children's Hospital Los Angeles, Department of Pediatrics, Division of Hematology and Oncology, Cancer and Blood Disease Institute, Keck School of Medicine, University of Southern California, USA)

十、临床药代动力学 (2024年第63卷第1期)

January 2024 -Volume 63 - Issue 1 (2024年1月第63卷第1期)
https://link.springer.com/journal/40262/volumes-and-issues/63-1

Review Article(综述文章)
1. 在抗菌和抗真菌药物开发过程中,应将肥胖患者视为一个特殊的患者群体;行动呼吁
(Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action)
作者:K. P. van Rhee* (Department of Clinical Pharmacy Tergooi MC, The Netherlands)
2. EMA批准的抗真菌药物研发过程中的临床前药代动力学/药效学研究和临床试验:一项综述
(Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review)
作者:Theresa Pecho, Markus Zeitlinger* (Department of Clinical Pharmacology, Medical University of Vienna, Austria)
3. 奈玛特韦/利托那韦的临床药代动力学、药效学和药物相互作用的全面综述
(A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir)
作者:Jacqueline Gerhart* (Pfizer Inc, Research and Development, USA)

Original Research Article(原创研究文章)
1. UDP葡糖醛酸基转移酶和CYP2C8在CYP2C8介导的药物氧化中的相互作用及其对标准化CYP2C8抑制剂、氯吡格雷和吉非罗齐产生的药物相互作用的影响
(Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil)
作者:Katsumi Iga* (Pharmaceutical Research and Technology Unit, R & D Division, Pre-formulation Department, Towa Pharmaceutical Co., Ltd,  Japan)
2. 抗SARS-CoV-2单克隆抗体Sotrovimab在日本和高加索健康志愿者中静脉注射或肌肉注射的药代动力学、安全性和耐受性
(Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers)
作者:Ahmed Nader* (Clinical Pharmacology Modelling and Simulation, GSK, USA)
3. 基于胎儿生理的通用药代动力学模型的建立及头孢呋辛人母体和胎儿器官浓度的预测
(Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime)
作者:Xiaomei I. Liu* (Division of Clinical Pharmacology, Children's National Hospital, USA)
4. 在AUC 400-600 mg·h/L目标剂量的新时代,万古霉素在肥胖和肥胖肾功能变化患者中如何给药
(How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing)
作者:Tan Zhang, Catherijne A. J. Knibbe* (Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, The Netherlands)
5. 葡萄糖激酶激活剂PB201在健康志愿者和2型糖尿病患者中的群体药动学/药效学分析:促进PB201在中国的临床发展
(Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China)
作者:Ling Song, Fangrui Cao, Dongyang Liu* (Drug Clinical Trial Center, Peking University Third Hospital, China)
6. 与正常体重患者比较,肥胖患者在胃旁路术或严格饮食前后的地高辛药代动力学
(Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals)
作者:Kine Eide Kvitne* (Department of Pharmacy, University of Oslo, Blindern, Norway)
7. 头孢他林强化给药关键成分对药代动力学/药效学目标实现的影响
(Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment)
作者:Iris K. Minichmayr* (Department of Clinical Pharmacology, Medical University of Vienna, Austria)

网友评论